AC
The startup develops an investigational enzyme replacement therapy that combines recombinant human alpha-N-acetylglucosaminidase with a peptide derived from insulin-like growth factor 2. This therapy targets rare pediatric neurodegenerative diseases, providing a potential treatment option for children suffering from these debilitating conditions.
Updated 2 months ago
Funding
Funding not disclosed
NHFunding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops an investigational enzyme replacement therapy that combines recombinant human alpha-N-acetylglucosaminidase with a peptide derived from insulin-like growth factor 2. This therapy targets rare pediatric neurodegenerative diseases, providing a potential treatment option for children suffering from these debilitating conditions.